Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT03519412 |
TitlePembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status | Phase
Phase 2
|
Date Added 2018-05-09 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar |
Tags
MSS/ MMRp
|
NCT ID NCT02886585 |
TitlePembrolizumab In Central Nervous System Metastases | Phase
Phase 2
|
Date Added 2016-09-01 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Pembrolizumab |
Tags
MSS/ MMRp
|
NCT ID NCT04963283 |
TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-07-15 |
Location
Colorado, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Cabozantinib, Nivolumab |
Tags
MSS/ MMRp
|
NCT ID NCT03977090 |
TitleGeptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2019-06-06 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Geptanolimab Injection, Elunate |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02298959 |
TitleTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | Phase
Phase 1
|
Date Added 2014-11-24 |
Location
Florida, United States
Maryland, United States Massachusetts, United States Canada |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap |
Tags
MSS/ MMRp
|
NCT ID NCT03844750 |
TitlePembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | Phase
Phase 2
|
Date Added 2019-02-18 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Vactosertib, Keytruda |
Tags
MSS/ MMRp
|
NCT ID NCT05243862 |
TitleSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | Phase
Phase 2
|
Date Added 2022-02-17 |
Location
Arizona, United States
Florida, United States Minnesota, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab, PolyPEPI1018, Tecentriq |
Tags
MSS/ MMRp
|
NCT ID NCT04776148 |
TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | Phase
Phase 3
|
Date Added 2021-03-01 |
Location
California, United States
Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Korea, Republic of Russian Federation Spain Taiwan Turkey United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil) |
Tags
MSS/ MMRp
|
NCT ID NCT04653480 |
TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | Phase
Phase 2
|
Date Added 2020-12-04 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy, Surufatinib, Toripalimab |
Tags
MSS/ MMRp
|
NCT ID NCT03925662 |
TitleMebendazole as Adjuvant Treatment for Colon Cancer | Phase
Phase 3
|
Date Added 2019-04-24 |
Location
Egypt
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Folfox with avastin, Mebendazole |
Tags
MSI-H/ MMRd, MSS/ MMRp
|